bioecon Member area
Technology · Services, governance & capital / Regulatory & legal

Biotech IP valuation

Consultancies and data platforms that value biotechnology and pharmaceutical patent portfolios for licensing negotiations, M&A, litigation and capital raises — translating a patent estate covering therapeutics, diagnostics or platform technologies into a defensible monetary figure.

Tech Policy & Assessment Risk: low Services US · EU · IN · CN verified 2026-08-16 · 10 Sources (0 independent)

1 · What it gives

Biotech IP valuation is a B2B services category in which specialist consultancies and data platforms assign a defensible monetary value to a biotechnology or pharmaceutical company’s patent portfolio, supporting licensing negotiations, M&A due diligence, litigation damages and capital raises. Ocean Tomo runs engagement-based valuations for biotechnology startups, including a documented capital-raise engagement for a company holding IP covering cancer and rare-disease therapeutics and diagnostics. Consor IP Consulting applies AI-assisted methods to patent valuation, treating patents as strategic business assets rather than purely legal instruments. Charles River Associates (CRA) brings economic-valuation expertise to life-sciences disputes, including cases where the product being valued may never reach market — a distinctly biotech valuation problem. EverEdge Global, headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios. GreyB provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — built for IP counsel and licensing teams assessing monetization readiness, including standard-essential-patent (SEP) readiness reporting. Inngot, a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets for smaller biotech and life-sciences companies.

The key directions of biotech IP valuation are:

  1. Engagement-based patent-portfolio valuation: custom valuations for a specific transaction — licensing negotiation, M&A, or a capital raise — grounded in the patent estate’s claims, remaining life and competitive position.
  2. AI-assisted valuation methodology: applying machine-learning and data-driven models to patent valuation, moving beyond purely qualitative expert judgment.
  3. Litigation and damages valuation: economic analysis supporting patent-infringement and licensing disputes, including cases involving products that have not yet reached market approval.
  4. Portfolio analytics and monetization readiness: structured analysis of prosecution history, litigation exposure, claims and citations to assess which patents in a portfolio are genuinely ready for licensing or sale.

Sectoral value chain#

[Patent portfolio identification] ──> [Prior-art & claims analysis] ──> [Valuation methodology selection]
                                                                    │
                                                        (Royalty-rate benchmarking)
                                                                    │
              [Negotiation/litigation support] <──── [Valuation report delivery] <─── [Monetary value determination]

Value chain levels#

LevelDescriptionKey inputs/outputs
Portfolio identificationCataloguing the patents, applications and other intangible assets that make up the biotech company’s IP estate.In: Patent filings, R&D records.
Out: IP asset inventory.
Prior-art and claims analysisAssessing patent strength, remaining life, prosecution history and litigation exposure for each asset.In: IP asset inventory, prosecution files.
Out: Patent-strength assessment.
Valuation methodology selectionChoosing an income-, market- or cost-based valuation approach suited to the asset class and the transaction context.In: Patent-strength assessment.
Out: Selected valuation methodology.
Royalty-rate benchmarkingComparing the asset against comparable licensing deals and royalty-rate data to ground the valuation in market evidence.In: Selected valuation methodology, deal-comparable data.
Out: Benchmarked royalty range.
Monetary value determinationProducing a defensible monetary valuation figure or range for the patent or portfolio.In: Benchmarked royalty range.
Out: Valuation figure/range.
Valuation report deliveryDelivering the finished valuation report to support the client’s licensing negotiation, M&A process or litigation.In: Valuation figure/range.
Out: Delivered valuation report.

Cross-cutting technologies of the sector:

  • Patent-valuation methodologies: income-, market- and cost-based approaches adapted to the specific characteristics of a biotech or pharmaceutical patent estate.
  • Royalty-rate benchmarking databases: structured datasets of comparable licensing deals used to ground a valuation in observed market royalty rates.
  • IP-portfolio analytics: software analyzing prosecution history, litigation exposure, claims and citations to assess a patent portfolio’s monetization readiness.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Patent portfolio identification
    The valuation firm catalogues the patents, applications and other intangible assets that make up the biotech company’s IP estate.
  2. 2
    Prior-art and claims analysisTesting & analytics
    Analysts assess patent strength, remaining life, prosecution history and litigation exposure for each asset in the portfolio.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Turion Labs Singapore
    “Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
    ✓ ISO 9001 industrial scale
    “As a contract research organization (CRO), we provide smart, rapid, and effective solutions using cutting-edge technologies to drive customer success.”
    industrial scale
    “ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
  3. 3
    Valuation methodology selection
    An income-, market- or cost-based valuation approach is selected to fit the specific asset class and the transaction context (licensing, M&A, litigation, capital raise).
  4. 4
    Royalty-rate benchmarking
    The asset is compared against comparable licensing deals and royalty-rate data to ground the valuation in observed market evidence rather than pure theory.
  5. 5
    Monetary value determination
    The methodology and benchmark data are combined to produce a defensible monetary valuation figure or range for the patent or portfolio.
  6. 6
    Valuation report delivery
    The finished valuation report is delivered to support the client’s licensing negotiation, M&A process, capital raise or litigation.

4 · Who delivers

Matched suppliers (matched automatically)

Tsingke BiotechnologyChinaProduceractive
CodexisUnited StatesProduceractive
BBCA Group 丰原集团ChinaProduceractive
Insilico MedicineCayman IslandsProduceractive
GranBioBrazilProduceractive
Life3 BiotechSingaporeProduceractive
Huazhi Rice Gene TechnologyChinaServices / consultingactive
United TherapeuticsUnited StatesProduceractive
Roche HoldingSwitzerlandProduceractive

In the services and supply catalogue 1 · paid service

Consulting & market access

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Ocean Tomo🇺🇸 USAEngagement-based IP valuationBiotech startup capital-raise supportcommercial
Consor IP Consulting🇺🇸 USAAI-assisted patent valuationData-driven valuation methodologycommercial
Charles River Associates IP🇺🇸 USAEconomic/IP litigation valuationLife-sciences disputes practicecommercial
EverEdge Global🇳🇿 New ZealandTen-asset-class valuation modelsPharma/biotech IP asset coveragecommercial
GreyB🇮🇳 IndiaIP Compass portfolio analyticsSEP readiness, litigation exposure analysiscommercial
Inngot🇬🇧 United KingdomIntangible-asset valuation toolkitSized for smaller biotech clientscommercial

5 · Rules & route to market

United States

The United States hosts the largest concentration of biotech IP-valuation consultancies and royalty-rate data providers, several built on decades of patent-litigation and licensing-deal history.

Ocean Tomo’s engagement-based startup valuations, Consor’s AI-assisted methodology, CRA’s life-sciences litigation valuation#

  • Ocean Tomo: runs engagement-based IP valuations for biotechnology startups, including capital-raise support for companies holding therapeutic and diagnostic patent portfolios.
  • Consor IP Consulting: applies AI-assisted methods to patent valuation, treating patents as strategic business assets in a data-driven valuation practice.
  • Charles River Associates (CRA): brings economic-valuation expertise to life-sciences disputes, including the distinctly biotech problem of valuing a product that may never reach market approval.

European Union

Europe and adjacent jurisdictions host specialist IP-valuation and intangible-asset consultancies serving smaller biotech and life-sciences clients alongside larger transactions.

EverEdge’s ten-asset-class valuation models, GreyB’s portfolio analytics, Inngot’s intangible-asset toolkit#

  • EverEdge Global: headquartered in New Zealand, publishes valuation models spanning ten distinct IP asset classes relevant to pharmaceutical and biotech portfolios.
  • GreyB: provides patent-portfolio analytics — prosecution history, litigation exposure, claims and citation analysis — including standard-essential-patent readiness reporting for licensing teams.
  • Inngot: a UK firm founded in 2007, provides a toolkit for identifying and valuing intellectual property and other intangible assets, sized for smaller biotech and life-sciences companies.

China

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese biotech IP-valuation firms searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Chinese biotech companies pursuing cross-border licensing or M&A typically engage the global valuation firms listed here, or domestic state-linked asset-appraisal institutions whose specific biotech-IP practices could not be confirmed in this screen.

Cross-border biotech IP valuation served by global consultancies#

  • Cross-border engagement pattern: Chinese biotech companies pursuing licensing deals or M&A with Western partners typically retain the global valuation firms listed in this article rather than a distinct domestic biotech-IP specialist.
  • Domestic gap: no Chinese-headquartered biotech IP-valuation firm confirmed by a live 2026 source was found during this screen.

6 · Money: tenders & grants

7 · Tech stack & innovations

The biotech IP-valuation technology stack combines established valuation methodology with AI-assisted analytics and structured royalty-benchmarking data:

  1. Patent-valuation methodologies:
    • Firms such as Ocean Tomo and Charles River Associates apply income-, market- and cost-based approaches adapted to biotech-specific circumstances, including products that have not yet reached regulatory approval.
  2. AI-assisted valuation and portfolio analytics:
    • Consor IP Consulting applies AI-assisted methods to patent valuation; GreyB’s IP Compass reviews prosecution history, litigation, claims and citations to assess monetization readiness.
  3. Royalty-rate benchmarking:
    • ktMINE maintains royalty-rate range data drawn from thousands of biopharma licensing deals, grounding valuations in observed market transactions.

Sources 10 · 0 independent · 10 producer sites

Producers' own sites 10

  1. Ocean tomo producer checked 2026-07-09 · link not kept
  2. Consor IP consulting producer checked 2026-08-08 · link not kept
  3. Cra IP valuation producer checked 2026-08-04 · link not kept
  4. Everedge global producer checked 2026-08-11 · link not kept
  5. Aon IP solutions producer checked 2026-08-05 · link not kept
  6. Greyb producer checked 2026-07-16 · link not kept
  7. Ktmine producer checked 2026-08-12 · link not kept
  8. Zhongjinhao asset appraisal producer checked 2026-08-16 · link not kept
  9. Inngot producer checked 2026-05-26 · link not kept
  10. China sciences exchange IP producer checked 2026-08-16 · link not kept